Skip to content

Nextech Invest Ltd.

Follow

13F filer, CIK 1595430, Zurich, Switzerland

Nextech Invest Ltd. reported $2,232,309,227 across 18 holdings for the quarter ended 2026-09-30, in a 13F-HR filed 2026-11-16. Its ten largest share positions make up 96.78% of the portfolio.

Accepted , ingested 13F-HR 0001595430-26-000015

Period
2026-09-30
Reported value
$2.23B
Holdings
18
Top 10 weight
96.78%
New
4
Sold out
1

Largest buys vs the previous quarter

SecurityShares changeApprox. value
ATTOnew+1,835,139$31.5M
ETRAnew+2,636,225$29.7M
AVTXnew+766,000$11.7M
BRVEnew+416,700$8.42M
SLNadded+740,740$8.1M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
ARVNexited-1,122,713-$17.1M
TYRAreduced-106,103-$2.32M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q3 2026

Share positions as resolved from 13F-HR 0001595430-26-000015, largest first. % of portfolio is the value over $2,232,309,227, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
RVMDREVOLUTION MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: 7,601,087 shares; 2025Q2: 7,601,087 shares; 2025Q3: 7,601,087 shares; 2025Q4: 7,601,087 shares; 2026Q1: 7,601,087 shares; 2026Q2: 7,601,087 shares; 2026Q3: 7,601,087 shares 7,601,087$1.56B69.89%0Timeline
PBLSPARABILIS MEDICINES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 4,663,176 shares; 2026Q3: 4,663,176 shares 4,663,176$151M6.75%0Timeline
RLAYRELAY THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: 3,846,409 shares; 2025Q2: 3,846,409 shares; 2025Q3: 3,846,409 shares; 2025Q4: 4,701,506 shares; 2026Q1: 5,526,506 shares; 2026Q2: 6,776,506 shares; 2026Q3: 6,776,506 shares 6,776,506$122M5.48%0Timeline
ORICORIC PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: 5,285,714 shares; 2025Q2: 7,162,637 shares; 2025Q3: 7,162,637 shares; 2025Q4: 7,162,637 shares; 2026Q1: 7,162,637 shares; 2026Q2: 7,162,637 shares; 2026Q3: 7,162,637 shares 7,162,637$96.5M4.32%0Timeline
TYRATYRA BIOSCIENCES INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: 4,055,861 shares; 2025Q2: 4,055,861 shares; 2025Q3: 4,055,861 shares; 2025Q4: 4,055,861 shares; 2026Q1: 4,055,861 shares; 2026Q2: 3,553,585 shares; 2026Q3: 3,447,482 shares 3,447,482$75.4M3.38%-106,103Timeline
ALMSALUMIS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: 1,476,998 shares; 2025Q2: 2,915,998 shares; 2025Q3: 2,915,998 shares; 2025Q4: 2,915,998 shares; 2026Q1: 3,540,998 shares; 2026Q2: 3,540,998 shares; 2026Q3: 4,550,998 shares 4,550,998$33.6M1.51%+1,010,000Timeline
ATTOATTOVIA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 1,835,139 shares 1,835,139$31.5M1.41%newTimeline
KYMRKYMERA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not reported; 2025Q2: 340,909 shares; 2025Q3: 340,909 shares; 2025Q4: 278,896 shares; 2026Q1: 278,896 shares; 2026Q2: 278,896 shares; 2026Q3: 278,896 shares 278,896$31.2M1.4%0Timeline
ETRAELECTRA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 2,636,225 shares 2,636,225$29.7M1.33%newTimeline
ZYMEZYMEWORKS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: 1,113,946 shares; 2025Q2: 1,113,946 shares; 2025Q3: 1,113,946 shares; 2025Q4: 1,113,946 shares; 2026Q1: 1,113,946 shares; 2026Q2: 1,113,946 shares; 2026Q3: 1,113,946 shares 1,113,946$29.5M1.32%0Timeline
SLNSILENCE THERAPEUTICS PLCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: 952,400 shares; 2025Q2: 952,400 shares; 2025Q3: 952,400 shares; 2025Q4: 952,400 shares; 2026Q1: 952,400 shares; 2026Q2: 952,400 shares; 2026Q3: 1,693,140 shares 1,693,140$18.5M0.83%+740,740Timeline
CTMXCYTOMX THERAPEUTICS INC.Quarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 4,449,932 shares; 2026Q2: 4,449,932 shares; 2026Q3: 4,449,932 shares 4,449,932$12.1M0.54%0Timeline
AVTXAVALO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 766,000 shares 766,000$11.7M0.53%newTimeline
GLUEMONTE ROSA THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: 279,237 shares; 2026Q1: 304,237 shares; 2026Q2: 761,153 shares; 2026Q3: 761,153 shares 761,153$9.08M0.41%0Timeline
BRVEBRAVEHEART BIO INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: not reported; 2026Q3: 416,700 shares 416,700$8.42M0.38%newTimeline
CRVSCORVUS PHARMACEUTICALS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: 450,000 shares; 2026Q2: 450,000 shares; 2026Q3: 450,000 shares 450,000$5.18M0.23%0Timeline
ENGNENGENE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: not reported; 2025Q2: not reported; 2025Q3: not reported; 2025Q4: not reported; 2026Q1: not reported; 2026Q2: 2,324,943 shares; 2026Q3: 2,324,943 shares 2,324,943$4.65M0.21%0Timeline
CNTXCONTEXT THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q4: not loaded; 2025Q1: 7,419,355 shares; 2025Q2: 7,419,355 shares; 2025Q3: 7,419,355 shares; 2025Q4: 7,419,355 shares; 2026Q1: 7,419,355 shares; 2026Q2: 7,419,355 shares; 2026Q3: 7,419,355 shares 7,419,355$2.23M0.1%0Timeline

Sold out in Q3 2026

Positions in the previous quarter's report that this quarter's report no longer lists.

SecurityShares beforeValue beforeType
ARVNARVINAS INC1,122,713$17.1Mshares

How Q3 2026 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001595430-26-000015 base2026-11-16